- Financing led by Engine Ventures with support from Amplify Partners, Starbloom Capital, Connecticut Innovations, and E1 Ventures- Proceeds to accelerate strategic partnerships and internal CNS development programs to showcase the predictive power of the fully integrated platform-

NEW HAVEN, Conn., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Bexorg, Inc., the first integrated AI and whole-human brain platform company transforming central nervous system (CNS) drug discovery and development, today announced the completion of a $23 million Series A financing led by Engine Ventures with participation from new investors Connecticut Innovations and E1 Ventures and existing investors Amplify Partners and Starbloom Capital. Bexorg has raised a total of $42.5 million to date.

Industry reports have found that the clinical trial failure rate in CNS drug development exceeds 95%, largely because cellular and animal models used in drug discovery inaccurately capture human biology. Bexorg is shifting this paradigm, with its platform based on comprehensive human datasets generated from wet-lab experimentation in a living system of diseased and non-diseased whole human brains. This data directly feeds AI models to generate high-fidelity targets, novel biomarkers, and go/no-go decisions with unprecedented accuracy and reliability.

"The support from this group of leading investors validates that Bexorg has established a new category of AI-enabled, whole human-brain infrastructure for ...